These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20099776)

  • 1. Prescribing medications and nutritional supplements for athletes.
    Babwah T
    West Indian Med J; 2009 Sep; 58(4):352-6. PubMed ID: 20099776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [World Football Championship 2006--anti-doping regulations].
    Wolfarth B; Graf-Baumann T; Halle M
    MMW Fortschr Med; 2006 Jun; 148(23):41-3. PubMed ID: 16826737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intended or Unintended Doping? A Review of the Presence of Doping Substances in Dietary Supplements Used in Sports.
    Martínez-Sanz JM; Sospedra I; Ortiz CM; Baladía E; Gil-Izquierdo A; Ortiz-Moncada R
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 28976928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.
    Di Luigi L; Pigozzi F; Sgrò P; Frati L; Di Gianfrancesco A; Cappa M
    J Endocrinol Invest; 2020 May; 43(5):563-573. PubMed ID: 31734891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
    Wolfarth B; Wuestenfeld JC; Kindermann W
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
    Striegel H; Rössner D; Simon P; Niess AM
    Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication use by athletes at the Athens 2004 Summer Olympic Games.
    Tsitsimpikou C; Tsiokanos A; Tsarouhas K; Schamasch P; Fitch KD; Valasiadis D; Jamurtas A
    Clin J Sport Med; 2009 Jan; 19(1):33-8. PubMed ID: 19124981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Between medical treatment and performance enhancement: an investigation of how elite athletes experience Therapeutic Use Exemptions.
    Overbye M; Wagner U
    Int J Drug Policy; 2013 Nov; 24(6):579-88. PubMed ID: 23582632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Doping-related problems in clinical practice].
    Villiger B; Monnat A
    Ther Umsch; 2001 Apr; 58(4):232-8. PubMed ID: 11344955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations.
    Allen H; Backhouse SH; Hull JH; Price OJ
    Sports Med; 2019 May; 49(5):659-668. PubMed ID: 30887312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The asthmatic athlete: inhaled Beta-2 agonists, sport performance, and doping.
    McKenzie DC; Fitch KD
    Clin J Sport Med; 2011 Jan; 21(1):46-50. PubMed ID: 21200170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Educational opportunities and anti-doping roles and responsibilities for pharmacists.
    Ambrose PJ
    Yakugaku Zasshi; 2011; 131(12):1761-4. PubMed ID: 22129874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of changes in anti-doping regulations (WADA Guidelines) on asthma care in athletes.
    Couto M; Horta L; Delgado L; Capão-Filipe M; Moreira A
    Clin J Sport Med; 2013 Jan; 23(1):74-6. PubMed ID: 22948449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatological prescribing in athletes: a review of the new World Anti-Doping Agency guidelines.
    Smith R; Barnsley L; Kannangara S; Mace A
    Rheumatology (Oxford); 2004 Dec; 43(12):1473-5. PubMed ID: 15292526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication use in athletes selected for doping control at the Sydney Olympics (2000).
    Corrigan B; Kazlauskas R
    Clin J Sport Med; 2003 Jan; 13(1):33-40. PubMed ID: 12544162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Athletes and Supplements: Prevalence and Perspectives.
    Garthe I; Maughan RJ
    Int J Sport Nutr Exerc Metab; 2018 Mar; 28(2):126-138. PubMed ID: 29580114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4. The use and misuse of performance-enhancing substances in sport.
    Orchard JW; Fricker PA; White SL; Burke LM; Healey DJ
    Med J Aust; 2006 Feb; 184(3):132-6. PubMed ID: 16460300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of drugs and nutritional supplements in top-level track and field athletes.
    Tscholl P; Alonso JM; Dollé G; Junge A; Dvorak J
    Am J Sports Med; 2010 Jan; 38(1):133-40. PubMed ID: 19812387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance-enhancing substances: what athletes are using.
    Krcik JA
    Cleve Clin J Med; 2001 Apr; 68(4):283, 288-9, 295-7 passim. PubMed ID: 11326808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.